Gustatory Dysfunction Among a Sample of Depressed Egyptian Adults Under Anti-depressants Therapy
NCT03599011 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 30
Last updated 2021-02-02
Summary
\- Assess gustatory thresholds among a sample of depressed Egyptian adults (age from 20 to 50 years old) under anti-depressants therapy ( for at least 3 months) using filter paper disc(FPD) method through a scoring system. - Determine the taste intensity at supra-threshold among these patients using a psychophysical method through a scoring system. - Identify possible modulators for developing gustatory dysfunction among these patients using a questionnaire ( appendix) with a binary measuring unit (yes/no).
Conditions
- Taste Disorders
Sponsors & Collaborators
-
Cairo University
lead OTHER
Eligibility
- Min Age
- 20 Years
- Max Age
- 50 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2020-02-22
- Primary Completion
- 2020-08-08
- Completion
- 2020-10-07
Countries
- Egypt
Study Locations
More Related Trials
-
Mood Effects of Serotonin Agonists
NCT03790358 ·Status: COMPLETED ·Phase: PHASE1
-
Mechanism of Antidepressant-Related Dysfunctional Arousal in High-Risk Youth
NCT02553161 ·Status: COMPLETED ·Phase: NA
-
Beta-CIT-SPECT and Neurophysiology in Depression
NCT00145132 ·Status: COMPLETED ·Phase: PHASE4
-
Dichotic Listening as a Predictor of Medication Response in Depression
NCT00404755 ·Status: COMPLETED ·Phase: PHASE4
-
Antidepressant Effects of TS-161 in Treatment-Resistant Depression
NCT04821271 ·Status: TERMINATED ·Phase: PHASE2
-
Hormone and Sleep Response to Antidepressant Treatment in Adolescents and Adults With Depression
NCT00106197 ·Status: UNKNOWN ·Phase: PHASE4
-
A Study to Test Different Doses of BI 1569912 in People With Depression
NCT06558344 ·Status: COMPLETED ·Phase: PHASE2
-
A Study of Aticaprant 10 Milligrams (mg) as Adjunctive Therapy in Adult Participants With MDD With Moderate-to-severe Anhedonia and Inadequate Response to Current Antidepressant Therapy
NCT05550532 ·Status: COMPLETED ·Phase: PHASE3
-
The Antidepressant Effects Of The NMDA Antagonist, CP-101,606, In Patients With MDD
NCT00163059 ·Status: COMPLETED ·Phase: PHASE2
-
Patient Tolerability Study of GSK163090
NCT00559299 ·Status: COMPLETED ·Phase: PHASE1
-
Role Of Ketamine in Treatment-Resistant Major Depressive Disorder And Its Effect on Suicidality
NCT04101474 ·Status: COMPLETED ·Phase: NA
-
Antidepressant Effects of the Glycine Receptor Antagonist AV-101 (4-chlorokynurenine) in Major Depressive Disorder
NCT02484456 ·Status: COMPLETED ·Phase: PHASE2
-
Neuropharmacologic Imaging and Biomarker Assessments of Response to Acute and Repeated-Dosed Ketamine Infusions in Major Depressive Disorder
NCT03065335 ·Status: RECRUITING ·Phase: PHASE1
-
Outcome Following Antidepressant Treatment on Possible Endo-Phenotypes for Major Depression
NCT00386841 ·Status: COMPLETED ·Phase: PHASE4
-
Effects of Antidepressant on Postsynaptic Signal Transduction in Serotonergic System of Depressed Patients
NCT01352572 ·Status: UNKNOWN ·Phase: NA
-
Flexible Dose Titration Add-on Study to Treat Major Depressive Disorder
NCT00593879 ·Status: COMPLETED ·Phase: PHASE2
-
Repeated Neurocognitive Measurements in Depressed Patients
NCT05991232 ·Status: WITHDRAWN ·Phase: PHASE1/PHASE2
-
Study to Evaluate the Efficacy, Safety and Tolerability of an Oral Aripiprazole/Escitalopram Combination Therapy in Participants With Major Depressive Disorder (MDD)
NCT01111539 ·Status: TERMINATED ·Phase: PHASE3
-
Does Enhanced Glutamate Transporter Function Produce Antidepressant Effects in People With Major Depression?
NCT02049385 ·Status: TERMINATED ·Phase: PHASE1/PHASE2
-
A Study of Different Titration Schedules of ALKS 5461 in Adults With Major Depressive Disorder (MDD)
NCT02085135 ·Status: COMPLETED ·Phase: PHASE3
-
Mechanisms of Antidepressant Non-Response in Late-Life Depression
NCT01931202 ·Status: COMPLETED ·Phase: NA
-
A Study in Participants With Major Depressive Disorder (MDD) With Anhedonia and Inadequate Response to Current Antidepressant Therapy Including a Selective Serotonin Reuptake Inhibitor (SSRI) or Serotonin Norepinephrine Reuptake Inhibitor (SNRI)
NCT05841030 ·Status: COMPLETED
-
Study to Evaluate the Efficacy, Safety and Tolerability of an Oral Aripiprazole/Escitalopram Combination Therapy in Participants With Major Depressive Disorder (MDD)
NCT01111552 ·Status: TERMINATED ·Phase: PHASE3
-
Study of Antidepressant Efficacy of a Selective, High Affinity Enkephalinergic Agonist in Anxious Major Depressive Disorder (AMDD)
NCT00759395 ·Status: COMPLETED ·Phase: PHASE2
-
Comparison of Plasma Concentration Changes Between Two Types of Tablets of FK949E Administration to Patients With Major Depressive Disorder
NCT01919008 ·Status: COMPLETED ·Phase: PHASE1